PNI Therapeutics is at the forefront of developing digiceuticals, software as medicine, to augment and enhance standard-of-care treatments for cancer.
We recently completed a feasibility study among 36 cancer patients. Research shows a statistically significant improvement in patient-reported outcomes in their mental and physical health after using our VR application, PNI Thrive. The study results are in peer review and awaiting publication in Therapeutic Advances in Medical Oncology. We have the 2nd study in the works with a large medical center in New York and are awaiting Independent Review Board approval of our research protocol. Our mission is to quicken recovery, reduce mortality, and lower costs by increasing the efficacy of standard-of-care cancer treatments through VR. If you are a researcher, clinic, or a hospital interested in conducting a study regarding the use of VR among Oncology patients and would like to learn more, please get in touch with us.